BioSpace News Archive

The use of digital pathology has been largely restricted to research applications.

Amgen today announced that it will report its third quarter financial results on Wednesday, Oct. 25, 2017, after the close of the U.S. financial markets.

Janssen Biotech announced today that the FDA has approved SIMPONI ARIA (golimumab), the only fully-human anti-TNF-alpha therapy administered via a 30-minute infusion, for the treatment of adults with active psoriatic arthritis or active ankylosing spondylitis (AS).

Corrona and the National Multiple Sclerosis Society have announced their intent to collaborate on the launch of the MS Registry to study the comparative safety and effectiveness of approved MS therapies.

Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today that the results of the APOLLO Phase 3 study of patisiran in hereditary ATTR (hATTR) amyloidosis patients with polyneuropathy.

The Medicines Company will host a conference call on Wednesday, October 25, 2017, at 8:30 a.m., Eastern Time, to discuss its third-quarter 2017 financial results and operational developments.

Bristol-Myers Squibb Company today announced that new data across serious liver diseases, including nonalcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC), will be presented at The Liver Meeting 2017 in Washington, DC, October 20 - 24, 2017.

Mergenet Solutions of Coconut Creek, FL has declared a cash dividend.

ImmunoGen, Inc., a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, November 3, 2017 to discuss its third quarter 2017 financial results. Management also will provide a brief update on the business.

Concordia today announced that it has taken a further step in its previously announced efforts to realign its capital structure by commencing a court proceeding under the CBCA.